drugset / Trial / NCT00785941
A Study of IMC-A12 Every 2 Weeks in Patients With Tumors Who No Longer Respond to Treatment or No Treatment is Available
NaSingle-groupOpen-label
Summary
The purpose of this study is to determine if IMC-A12 is safe for patients, and also to determine the best dose of IMC-A12 to give to patients.
Timeline
- Start
- 2006-04
- Primary completion
- 2007-10
- Completion
- 2007-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cixutumumab | Monoclonal antibody | 6 mg/kg | Intravenous |
| Subject | Cixutumumab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | Cixutumumab | Monoclonal antibody | 15 mg/kg | Intravenous |
| Subject | Cixutumumab | Monoclonal antibody | 21 mg/kg | Intravenous |
| Subject | Cixutumumab | Monoclonal antibody | 27 mg/kg | Intravenous |